At the time of writing, Apogee Therapeutics Inc [APGE] stock is trading at $38.42, up 1.45%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APGE shares have gain 5.64% over the last week, with a monthly amount glided 6.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on July 07, 2025, when BTIG Research reiterated its Buy rating and also boosted its price target to $115 from $100. Previously, Citigroup started tracking the stock with Buy rating on March 13, 2025, and set its price target to $95. On November 25, 2024, Canaccord Genuity initiated with a Buy rating and assigned a price target of $89 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $80 on May 10, 2024. BTIG Research initiated its recommendation with a Buy and recommended $43 as its price target on December 20, 2023. Wedbush started tracking with a Outperform rating for this stock on August 08, 2023, and assigned it a price target of $40. In a note dated August 08, 2023, TD Cowen initiated an Outperform rating.
For the past year, the stock price of Apogee Therapeutics Inc fluctuated between $26.20 and $63.50. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $38.42 at the most recent close of the market. An investor can expect a potential return of 147.27% based on the average APGE price forecast.
Analyzing the APGE fundamentals
Gross Profit Margin for this corporation currently stands at -4.54% with Operating Profit Margin at -2083.29%, Pretax Profit Margin comes in at -1319.58%, and Net Profit Margin reading is -1319.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.23 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.68 points at the first support level, and at 36.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.99, and for the 2nd resistance point, it is at 39.55.
Ratios To Look Out For
It is important to note that Apogee Therapeutics Inc [NASDAQ:APGE] has a current ratio of 16.36. As well, the Quick Ratio is 16.36, while the Cash Ratio is 3.94.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on Sep 03 ’25 when 2725.0 shares were sold. Chief Medical Officer, Dambkowski Carl completed a deal on Aug 06 ’25 to sell 2725.0 shares. Meanwhile, Chief Medical Officer Dambkowski Carl sold 10090.0 shares on Jul 02 ’25.
